Endothelial deletion of Sag/Rbx2/Roc2 E3 ubiquitin ligase causes embryonic lethality and blocks tumor angiogenesis

Oncogene

Volumn 33, Issue 44, 2013, Pages 5211-5220

  Tan, M ^a   Li, H ^a   Sun, Y ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

angiogenesis; anti angiogenesis therapy; MLN4924; Sag cKO mouse model; SAG CRL E3 ligase; vasculogenesis

Indexed keywords

EID: 84887076655     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.473     Document Type: Article

References (49)

1. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78: 399-434.
2. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
3. Zhao Y, Sun Y. Cullin-RING ligases as attractive anti-cancer targets. Curr Pharm Des 2013; 19: 3215-3225.
4. Wu K, Fuchs SY, Chen A, Tan P, Gomez C, Ronai Z et al. The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol 2000; 20: 1382-1393.
5. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008; 134: 995-1006.
6. Goldenberg SJ, Cascio TC, Shumway SD, Garbutt KC, Liu J, Xiong Y et al. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 2004; 119: 517-528.
7. Kamura T, Conrad MN, Yan Q, Conaway RC, Conaway JW. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 1999; 13: 2928-2933.
8. Yamoah K, Oashi T, Sarikas A, Gazdoiu S, Osman R, Pan ZQ. Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad Sci USA 2008; 105: 12230-12235.
9. Willems AR, Schwab M, Tyers M. A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta 2004; 1695: 133-170.
10. Jia L, Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets 2011; 11: 347-356.
11. Duan H, Wang Y, Aviram M, Swaroop M, Loo JA, Bian J et al. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol Cell Biol 1999; 19: 3145-3155.
12. Sun Y, Tan M, Duan H, Swaroop M. SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid Redox Signal 2001; 3: 635-650.
13. Swaroop M, Wang Y, Miller P, Duan H, Jatkoe T, Madore SJ et al. Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germinatton: Chip profiling implicates its role in cell cycle regulation. Oncogene 2000; 19: 2855-2866.
14. Gu Q, Tan M, Sun Y. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetateinduced neoplastic transformation. Cancer Res 2007; 67: 3616-3625.
15. Tan M, Gu Q, He H, Pamarthy D, Semenza GL, Sun Y. SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1alpha ubiquitination and degradation. Oncogene 2008; 27: 1404-1411.
16. He H, Gu Q, Zheng M, Normolle D, Sun Y. SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis 2008; 29: 858-865.
17. Tan M, Gallegos JR, Gu Q, Huang Y, Li J, Jin Y et al. SAG/ROC-SCFbeta-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia 2006; 8: 1042-1054.
18. Tan M, Zhu Y, Kovacev J, Zhao Y, Pan ZQ, Spitz DR et al. Disruption of Sag/Rbx2/Roc2 induces radiosensitization by increasing ROS levels and blocking NF-kB activation in mouse embryonic stem cells. Free Radic Biol Med 2010; 49: 976-983.
19. Gu Q, Bowden GT, Normolle D, Sun Y. SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB. J Cell Biol 2007; 178: 1009-1023.
20. Jia L, Yang J, Hao X, Zheng M, He H, Xiong X et al. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res 2010; 16: 814-824.
21. Tan M, Zhao Y, Kim SJ, Liu M, Jia L, Saunders TL et al. SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell 2011; 21: 1062-1076.
22. Sun Y. Alteration of SAG mRNA in human cancer cell lines: requirement for the RING finger domain for apoptosis protection. Carcinogenesis 1999; 20: 1899-1903.
23. Yang GY, Pang L, Ge HL, Tan M, Ye W, Liu XH et al. Attenuation of ischemiainduced mouse brain injury by SAG, a redox-inducible antioxidant protein. J Cereb Blood Flow Metab 2001; 21: 722-733.
24. Sun Y, Li H. Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell 2013; 4: 103-116.
25. Duan H, Tsvetkov LM, Liu Y, Song Y, Swaroop M, Wen R et al. Promotion of S-phase entry and cell growth under serum starvation by SAG/ROC2/Rbx2/Hrt2, an E3 ubiquitin ligase component: association with inhibition of p27 accumulation. Mol Carcinog 2001; 30: 37-46.
26. Huang Y, Duan H, Sun Y. Elevated expression of SAG/ROC2/Rbx2/Hrt2 in human colon carcinomas: SAG does not induce neoplastic transformation, but its antisense transfection inhibits tumor cell growth. Mol Carcinog 2001; 30: 62-70.
27. Diez-Juan A, Castro C, Edo MD, Andres V. Role of the growth suppressor p27Kip1 during vascular remodeling. Curr Vasc Pharmacol 2003; 1: 99-106.
28. Schiappacassi M, Lovat F, Canzonieri V, Belletti B, Berton S, Di Stefano D et al. p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther 2008; 7: 1164-1175.
29. Park AY, Shen TL, Chien S, Guan JL. Role of focal adhesion kinase ser-732 phosphorylation in centrosome function during mitosis. J Biol Chem 2009; 284: 9418-9425.
30. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
31. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 2012; 72: 282-293.
32. Tan M, Davis SW, Saunders TL, Zhu Y, Sun Y. RBX1/ROC1 disruption results in early embryonic lethality due to proliferation failure, partially rescued by simultaneous loss of p27. Proc Natl Acad Sci USA 2009; 106: 6203-6208.
33. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005; 7: 51-63.
34. Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 2011; 17: 12-18.
35. Wang XQ, Lui EL, Cai Q, Ching WY, Liu KS, Poon RT et al. p27Kip1 promotes migration of metastatic hepatocellular carcinoma cells. Tumour Biol 2008; 29: 217-223.
36. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
37. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumorderived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59: 1592-1598.
38. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
39. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
40. Deshaies RJ, Emberley ED, Saha A. Control of cullin-RING ubiquitin ligase activity by Nedd8. In: Groettrup M (ed.). Conjugation and Deconjugation of Ubiquitin Family Modifiers. Subcellular Biochemistry: New York, 2010 41-56.
41. Xirodimas DP. Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem Soc Trans 2008; 36: 802-806.
42. Rabut G, Peter M. Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 969-976.
43. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010; 1: 708-716.
44. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009; 15: 3912-3916.
45. Nawrocki ST, Griffin P, Kelly KR, Carew JS. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs 2012; 21: 1563-1573.
46. Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P et al. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 2005; 169: 941-952.
47. Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 2001; 15: 859-876.
48. Zhao X, Peng X, Sun S, Park AY, Guan JL. Role of kinase-independent and-dependent functions of FAK in endothelial cell survival and barrier function during embryonic development. J Cell Biol 2010; 189: 955-965.
49. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL-and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005; 24: 7381-7388.